Sugi Predict

Sugi Predict / Compounds / SCHEMBL5064848

SCHEMBL5064848

SCHEMBL5064848

CN1c2ccc(C(=O)NCc3ccc(F)cc3)cc2N=C(c2ccc(F)cc2)c2ccccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 4/20 0.66
▸ DRD2 P14416 3/20 0.52
▸ RXRA P19793 3/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MAPT P10636 4/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ RARA P10276 1/20 0.47
▸ RARB P10826 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ AKT1 P31749 1/20 0.45
▸ PPARG P37231 1/20 0.45
▸ OPRD1 P41143 1/20 0.44
▸ OPRK1 P41145 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513437 0.89 CNR1 (0.66) CNR1DRD2SMN1; SMN2MAPTMAPK1
SCHEMBL13808190 0.87 CNR1 (0.61) CNR1DRD2RXRASMN1; SMN2MAPT
SCHEMBL14043598 0.87 CNR1 (0.66) CNR1DRD2SMN1; SMN2MAPTMAPK1
SCHEMBL13808196 0.87 CNR1 (0.59) CNR1DRD2RXRASMN1; SMN2MAPT
SCHEMBL13808194 0.86 CNR1 (0.62) CNR1DRD2RXRASMN1; SMN2MAPT
SCHEMBL13807854 0.85 CNR1 (0.64) CNR1DRD2SMN1; SMN2MAPTMAPK1
SCHEMBL13808195 0.85 CNR1 (0.57) CNR1DRD2RXRASMN1; SMN2MAPT
SCHEMBL14043602 0.85 CNR1 (0.61) CNR1DRD2SMN1; SMN2MAPTMAPK1
SCHEMBL13808197 0.84 CNR1 (0.59) CNR1DRD2RXRASMN1; SMN2MAPT
SCHEMBL13807859 0.84 CNR1 (0.62) CNR1DRD2SMN1; SMN2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008118141-A2 USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY ACADIA PHARMACEUTICALS INC. (US) 2008-10-02 — — WO disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 — — US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 — — US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 — — US disclosed
WO-2007047737-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105819-A1 CB-1 modulating compounds and their use CNR1, CNR2, FAAH CNR1 1/4885DRD2 751/4885RXRA 303/4885
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH CNR1 1/4885DRD2 751/4885RXRA 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.